tirzepatide vs semaglutide weight loss trials Frontiers Comparative efficacy and safety of

Strengths and weaknesses To the best of the authors knowledge, this is the first study that evaluated in a real-world setting the psychiatric adverse events associated with three anti-diabetic and anti-obesity GLP1 receptor agonist medications

Sickle cell anaemia and malaria

Both exercise enthusiasts and competitive athletes are often looking for ways to improve their athletic performance and shed body fat

According to the group of authors, these polyagonists are in all likelihood the next step towards a cure for diabetes and obesity. Comparable to bariatric surgery The authors report on various polyagonists that are currently being researched in clinical studies and show improved efficacy with each new generation. The latest triple agonists attack both the glucose-dependent insulinotropic peptide receptor (GIPR) and the receptors for glucagon-like peptide 1 (GLP1) and glucagon (GCG, a hormone from the pancreas)

The MHRA approval was supported by results from Novo Nordisk's OASIS clinical trial programme, which evaluated oral semaglutide in adults living with obesity or overweight with weight-related health conditions